China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

by Illumina. “The problem was we never had a commercial platform to be able to sequence it on.” The next-generation sequencing platform they developed and commercialized by June 2006 ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, reaching US$ ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Illumina will expand its TruSight Oncology portfolio with the introduction of the TruSight Oncology 500 v2 (TSO 500 v2), a new version of its flagship next-generation sequencing (NGS) cancer assay ...

Angle announces new results for dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform: London Saturday, February 1, 2025, 15:00 Hrs [IST] Angle plc, a wo ...

Synaffix’s patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing products. Published first on TheFly – the ultimate source for real-time ...

Over the last six months, ANGLE has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...

Illumina Protein Prep™, powered by SOMAmer® technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insight Illumina, Inc. (NASDAQ:ILMN ...